Private company

Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is an American pharmaceutical preparations company based in Nashville.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersNashville, United States2
  • Incorporated inDE3
  • Business address1222 Demonbreun Street, Suite 2000, Nashville, Tn 372033
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300N33TFDZHS81H112
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 30740072

See how the biggest companies compare on our leaderboards

Unless expressly indicated or the context requires otherwise, the terms “Revance,” “Company,” “we,” “us,” and “our,” in this Annual Report on Form 10-K (this “Report”) refer to Revance Therapeutics, Inc., a Delaware corporation, and, where appropriate, its wholly-owned subsidiaries. We also have used several other terms in this Report, the consolidated financial statement and accompanying notes included herein, most of which are explained or defined below.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-135.4%Operating margin6
-138.4%Net margin6
76.5%Revenue growth, 20236
-$223.5MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development20¢$79.4M
  • Selling, general and admin75¢$297.7M
  • Interest5¢$19.4M
  • Income tax0¢$300.0K

Out of $234.0M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$234.0M in 2023+89228% since 2017
0$100.0M$200.0M$300.0M2017: $262.0K$262.0K20172018: $3.7M$3.7M2018+1323%2019: $413.0K$413.0K2019−89%2020: $15.3M$15.3M2020+3611%2021: $77.8M$77.8M2021+408%2022: $132.6M$132.6M2022+70%2023: $234.0M$234.0M2023+77%
Operating income789106-$316.8M in 2023+163% since 2017
-$400.0M-$300.0M-$200.0M-$100.0M02017: -$120.4M-$120.4M20172018: -$142.6M-$142.6M2018+18%2019: -$164.5M-$164.5M2019+15%2020: -$273.2M-$273.2M2020+66%2021: -$274.7M-$274.7M2021+1%2022: -$342.0M-$342.0M2022+24%2023: -$316.8M-$316.8M2023−7%
Net income789106-$324.0M in 2023+169% since 2017
-$400.0M-$300.0M-$200.0M-$100.0M02017: -$120.6M-$120.6M20172018: -$142.6M-$142.6M2018+18%2019: -$159.4M-$159.4M2019+12%2020: -$282.1M-$282.1M2020+77%2021: -$281.3M-$281.3M2021−0%2022: -$356.4M-$356.4M2022+27%2023: -$324.0M-$324.0M2023−9%
Fiscal year2017201820192020202120222023
Revenue$262.0K7$3.7M8$413.0K9$15.3M10$77.8M6$132.6M6$234.0M6
Research and development$80.4M7$92.5M8$102.9M9$125.8M10$116.3M6$101.3M6$79.4M6
Selling, general and admin$37.4M7$53.9M8$62.0M9$151.8M10$198.8M6$223.9M6$297.7M6
Operating income-$120.4M7-$142.6M8-$164.5M9-$273.2M10-$274.7M6-$342.0M6-$316.8M6
Interest$457.0K7$44.0K8$09$15.1M10$6.3M6$16.5M6$19.4M6
Income tax$07$3.0M8$09-$2.6M10$06$700.0K6$300.0K6
Net income-$120.6M7-$142.6M8-$159.4M9-$282.1M10-$281.3M6-$356.4M6-$324.0M6
Earnings per share-$3.679-$4.8610-$4.176-$4.906-$3.836
Earnings per share (diluted)-$3.679-$4.8610-$4.176-$4.906-$3.836
Shares (weighted, basic)67.5M shares672.7M shares684.6M shares6
Shares (weighted, diluted)67.5M shares672.7M shares684.6M shares6

Compare Revance Therapeutics, Inc. with another company

Corporate structure

Revance Therapeutics, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Revance Therapeutics, Inc.

  • Beryl Capital Management LLC Filed SCHEDULE 13G/A on Revance Therapeutics, Inc., latest May 15, 2025 (3 filings since Sep 16, 2024)
  • GLAZER CAPITAL, LLC Filed SCHEDULE 13G/A on Revance Therapeutics, Inc., latest May 15, 2025 (2 filings since Feb 6, 2025)
  • JPMorgan Chase Filed SCHEDULE 13G/A on Revance Therapeutics, Inc., latest Mar 6, 2025 (7 filings since Jan 18, 2022)
  • Palo Alto Investors LP Filed SCHEDULE 13G/A on Revance Therapeutics, Inc., latest Feb 13, 2025 (4 filings since Feb 14, 2022)
  • Teoxane SA Filed SCHEDULE 13D/A on Revance Therapeutics, Inc., latest Jan 30, 2025 (5 filings since Sep 1, 2023)
  • Franklin Templeton Investments Filed SCHEDULE 13G/A on Revance Therapeutics, Inc., latest Oct 31, 2024 (2 filings since Feb 6, 2024)
  • GIC Private Limited Filed SC 13G/A on Revance Therapeutics, Inc., latest Oct 23, 2024 (4 filings since Feb 8, 2022)
  • Capital World Investors Filed SC 13G/A on Revance Therapeutics, Inc., latest Oct 7, 2024 (6 filings since Feb 11, 2022)
  • Antara Capital LP Filed SC 13G/A on Revance Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Polar Capital Holdings Plc Filed SC 13G/A on Revance Therapeutics, Inc., latest Feb 13, 2024 (2 filings since Feb 14, 2023)
  • VANGUARD GROUP INC Filed SC 13G/A on Revance Therapeutics, Inc., latest Feb 13, 2024 (3 filings since Feb 10, 2022)
  • Wellington Management Company Filed SC 13G/A on Revance Therapeutics, Inc., latest Feb 4, 2022
  • Revance Therapeutics, Inc. Nashville, Tennessee, United States
    • 1. Hint, Inc. (d/b/a HintMD), incorporated in Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Revance Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$50.7M10 Dec 31, 2022$48.0M10 Dec 31, 2021+5.7%
Accumulated depreciation$28.6M10 Dec 31, 2022$23.3M10 Dec 31, 2021+22.6%
Property and equipment, net$17.2M6 Dec 31, 2023$13.8M6 Dec 31, 2022+24.8%
Finance-lease assets$19.8M6 Dec 31, 2023$6.4M6 Dec 31, 2022+209.9%
Operating-lease assets (leased space)$53.2M6 Dec 31, 2023$39.2M6 Dec 31, 2022+35.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$137.3M6 Dec 31, 2023$109.0M6 Dec 31, 2022+26.0%
Marketable securities, current$116.6M6 Dec 31, 2023$231.7M6 Dec 31, 2022−49.7%
Debt securities available for sale$225.9M6 Dec 31, 2023$321.4M6 Dec 31, 2022−29.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$06 Dec 31, 2023$77.2M6 Dec 31, 2022−100.0%
Intangible assets, net (excluding goodwill)$9.8M6 Dec 31, 2023$35.3M6 Dec 31, 2022−72.2%
Accumulated amortization$41.9M6 Dec 31, 2023$55.3M6 Dec 31, 2022−24.2%
Finite-lived intangibles, net$9.8M6 Dec 31, 2023$27.0M10 Dec 31, 2022−63.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$45.6M6 Dec 31, 2023$18.3M6 Dec 31, 2022+148.7%
Raw materials$3.9M6 Dec 31, 2023$505.0K6 Dec 31, 2022+679.8%
Work in process$17.4M6 Dec 31, 2023$4.9M6 Dec 31, 2022+253.1%
Finished goods$24.2M6 Dec 31, 2023$12.9M6 Dec 31, 2022+88.0%

Leadership

Who has led Revance Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. L. Daniel Browne2014–2019

President

  1. L. Daniel Browne2014–2019
  2. Todd Erik Zavodnick2018
  3. Abhay Joshi2020–2022
  4. Aubrey Rankin2020–2021
  5. Dustin S. Sjuts2021–2024

Chief financial officer

  1. Lauren P. Silvernail2014–2018
  2. Tobin Schilke2018–2025

Chief operating officer

  1. Abhay Joshi2015–2022
201520202025
Board members and other officers (26)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • 1. Hint, Inc. (d/b/a HintMD), incorporated in Delaware.4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Feb 6, 20258-K Entered a material agreement; Completed an acquisition or sale; Debt or obligation accelerated48
  2. Jan 21, 20258-K Entered a material agreement; Other events49
  3. Dec 12, 20248-K Entered a material agreement50
  4. Dec 9, 20248-K Entered a material agreement; Other events51
  5. Dec 5, 20248-K Other events52
  6. Dec 3, 20248-K Other events53
  7. Nov 29, 20248-K Other events54
  8. Nov 26, 20248-K Other events55
  9. Nov 19, 20248-K Other events56
  10. Nov 12, 20248-K Other events57
  11. Nov 7, 20248-K Results of operations58
  12. Nov 1, 20248-K Other events59
  13. Feb 5, 2014New chief executive L. Daniel Browne becomes CEO16
  14. Aug 10, 1999Founded Revance Therapeutics, Inc. is founded2

Calendar

When it reported results

  1. Nov 7, 2024Reported quarterly or annual results58
  2. Aug 8, 2024Reported quarterly or annual results60
  3. May 9, 2024Reported quarterly or annual results61
  4. Feb 28, 2024Reported quarterly or annual results62
  5. Jan 8, 2024Reported quarterly or annual results63
  6. Nov 8, 2023Reported quarterly or annual results64
  7. Aug 8, 2023Reported quarterly or annual results65
  8. May 9, 2023Reported quarterly or annual results66

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

326 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 59 major events, 135 insider forms, 41 large holders, 78 other. The latest 20:

  1. May 15, 2025SCHEDULE 13G/A EDGAR
  2. May 15, 2025SCHEDULE 13G/A EDGAR
  3. Mar 6, 2025SCHEDULE 13G/A EDGAR
  4. Feb 18, 202515-12G EDGAR
  5. Feb 13, 2025SCHEDULE 13G/A EDGAR
  6. Feb 12, 2025S-8 POS EDGAR
  7. Feb 12, 2025S-8 POS EDGAR
  8. Feb 12, 2025S-8 POS EDGAR
  9. Feb 12, 2025S-8 POS EDGAR
  10. Feb 12, 2025S-8 POS EDGAR
  11. Feb 12, 2025S-8 POS EDGAR
  12. Feb 12, 2025S-8 POS EDGAR
  13. Feb 12, 2025S-8 POS EDGAR
  14. Feb 12, 2025S-8 POS EDGAR
  15. Feb 12, 2025S-8 POS EDGAR
  16. Feb 12, 2025S-8 POS EDGAR
  17. Feb 12, 2025S-8 POS EDGAR
  18. Feb 12, 2025S-8 POS EDGAR
  19. Feb 12, 2025S-8 POS EDGAR
  20. Feb 12, 2025POSASR EDGAR

The 326 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

34 open-market trades by officers, directors and large owners since October 2021: 4 buys and 30 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 18, 2024Hollander DavidCMO & Global Therapeutics LeadSale3,908$4.17$16.3KForm 4
Apr 16, 2024Jordan EricaChief Commercial OfficerSale2,392$3.80$9.1KForm 4
Mar 18, 2024Sjuts Dustin SPresidentSale9,211$5.04$46.4KForm 4
Mar 18, 2024Moxie DwightCLO & GCSale8,125$5.04$41.0KForm 4
Mar 18, 2024Schilke TobinCFOSale9,361$5.04$47.2KForm 4
Mar 6, 2024Foley Mark JPresident & CEOBuy30,000$6.98$209.4KForm 4
Sep 6, 2023Moxie DwightCLO & GCSale11,000$17.06$187.7KForm 4
Sep 5, 2023Moxie DwightCLO & GCSale23,853$17.81$424.8KForm 4
Aug 3, 2023Foley Mark JPresident & CEOSale26,279$22.57$593.1KForm 4
Jul 3, 2023Schilke TobinCFOSale1,701$25.04$42.6KForm 4
Jul 3, 2023Foley Mark JPresident & CEOSale26,279$24.94$655.4KForm 4
Jun 15, 2023Kolaja Carey OConnorDirectorSale2,500$28.24$70.6KForm 4
Jun 9, 2023Sjuts Dustin SPresidentSale5,000$30.82$154.1KForm 4
Jun 9, 2023Foley Mark JPresident & CEOSale31,279$30.72$960.9KForm 4
Jun 2, 2023Schilke TobinCFOSale500$31.00$15.5KForm 4
Jun 1, 2023Schilke TobinCFOSale2,701$30.57$82.6KForm 4
May 15, 2023Moxie DwightCLO & GCSale21,401$34.55$739.4KForm 4
May 15, 2023Schilke TobinCFOSale21,401$34.55$739.4KForm 4
May 15, 2023Foley Mark JPresident & CEOSale70,447$34.55$2.4MForm 4
May 15, 2023Sjuts Dustin SPresidentSale21,015$34.55$726.1KForm 4

All 34 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Revance Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRevance Therapeutics, Inc.1
  • CIK0001479290
  • Employer ID (EIN)77-05516451
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1222 Demonbreun Street, Suite 2000, Nashville, TN 372031
  • Phone61572477551
  • Shares outstanding104,902,388 as of Oct 31, 202413
  • Public float$2.2B as of Jun 30, 20236
  • On EDGAR sinceDec 23, 20091
  • Filings947 in all: 4 (398), 8-K (172), SC 13G/A (64), 10-Q (33), 3 (33), 144 (23), SC 13G (17), 424B5 (16)1
    All 53 form types

    S-8 (14), S-8 POS (14), CT ORDER (12), UPLOAD (12), 10-K (11), 4/A (11), DEF 14A (11), 425 (10), CORRESP (8), SC 14D9/A (7), D/A (6), DEFA14A (6), EFFECT (6), D (5), SC TO-T/A (5), SCHEDULE 13G/A (5), S-1/A (4), S-3 (3), S-3ASR (3), SC TO-C (3), SC14D9C (3), SCHEDULE 13D/A (3), SCHEDULE 13G (3), 424B4 (2), DRS/A (2), S-1 (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B3 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), DRS (1), FWP (1), POSASR (1), PRE 14A (1), S-1MEF (1), S-4 (1), S-4/A (1), SC 13D (1), SC 13D/A (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2024
    Quarterly report (10-Q) Nov 7, 2024
    Proxy statement (DEF 14A) Mar 21, 2024
    Latest 8-K (8-K) Feb 6, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
    SEC EDGAROther events
  54. 54
    SEC EDGAROther events
  55. 55
    SEC EDGAROther events
  56. 56
    SEC EDGAROther events
  57. 57
    SEC EDGAROther events
  58. 58
  59. 59
    SEC EDGAROther events
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78